Celebrex in ALS   Principal Investigator     Merit Cudkowicz, MD Massachusetts General Hospital/Harvard Medical School, Boston, Massachusetts   Berman Center Site Investigator     William David, MD, PhD   Berman Center Site Coordinator     Shirley Conn, RN 612-341-7907   Description     This study enrolled 300 ALS patients across the U.S., whose disease duration had been less than two years. It was a placebo-controlled, double-blinded study to evaluate the efficacy of Celebrex in slowing the progression of ALS during the 12-month intervention period.   Role of the Berman Center     The Berman Center recruited and enrolled 10 participants. Participants attended 8 study visits at the Berman Center during the intervention year. At these visits, Berman Center doctors, research nurses, physical therapists, and respiratory therapists took study outcome measurements, which included a motor unit estimate, qualitative muscle test, blood tests, forced vital capacity test, and weight and vital sign measurements.